Development of a DNA Methylation-Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma.

Kevin BrennanThomas J MetznerChia-Sui KaoCharles E MassieGrant D StewartRobert W Haile James D BrooksMegan P HitchinsJohn T Leppert Olivier Gevaert

Published in: JCO precision oncology (2020)

This CpG signature could be developed as a clinical biomarker to support differential diagnosis of oncocytoma and chRCC in surgical samples. With improved biopsy techniques, this signature could be applied to preoperative biopsy specimens.

Keyphrases

dna methylation
fine needle aspiration
renal cell carcinoma
ultrasound guided
genome wide
gene expression
patients undergoing